Abstract
The targeting of anti-apoptotic members of the Bcl-2 family of proteins, especially Bcl-2, is the focus of efforts to modulate the intrinsic pathway of apoptosis and effect tumor death. Current understanding of the role of Bcl-2 family proteins and strategies and recent developments in drug inhibitors of these proteins, particularly antisense oligonucleotides and targeted small molecules, are reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
